CytomX Therapeutics to Hold 2024 Annual Meeting of Stockholders on May 15, 2024
Ticker: CTMX · Form: DEF 14A · Filed: Apr 4, 2024 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | DEF 14A |
| Filed Date | Apr 4, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy statement, annual meeting, stockholder vote, authorized shares, executive compensation
TL;DR
<b>CytomX Therapeutics will hold its 2024 Annual Meeting online on May 15, 2024, to elect directors, ratify auditors, and vote on increasing authorized shares.</b>
AI Summary
CytomX Therapeutics, Inc. (CTMX) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. CytomX Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on May 15, 2024, at 1:00 p.m. Pacific Time. The meeting will be conducted entirely online, accessible via www.virtualshareholdermeeting.com/CTMX2024. Key agenda items include electing three directors, ratifying Ernst & Young LLP as independent auditors, and approving an amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares. Stockholders will also vote on a non-binding advisory basis on the compensation of named executive officers. The record date for determining stockholders eligible to vote is March 19, 2024.
Why It Matters
For investors and stakeholders tracking CytomX Therapeutics, Inc., this filing contains several important signals. The company is seeking stockholder approval to double its authorized common stock from 150 million to 300 million shares, which could facilitate future fundraising or strategic transactions. The annual meeting will include a vote on executive compensation, providing shareholders an advisory say on pay practices.
Risk Assessment
Risk Level: low — CytomX Therapeutics, Inc. shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain new operational or financial information that would significantly alter the company's risk profile.
Analyst Insight
Stockholders should review the proposals regarding director elections, auditor ratification, and the significant increase in authorized shares before the May 15, 2024 meeting.
Key Numbers
- May 15, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 1:00 p.m. Pacific Time — Annual Meeting Time (2024 Annual Meeting of Stockholders)
- March 19, 2024 — Record Date (for determining stockholder eligibility to vote)
- 3 — Directors to be Elected (with terms to expire at the 2027 Annual Meeting)
- 150,000,000 — Current Authorized Shares (of common stock)
- 300,000,000 — Proposed Authorized Shares (of common stock after amendment)
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- Ernst & Young LLP (company) — independent registered public accounting firm
- May 15, 2024 (date) — 2024 Annual Meeting of Stockholders date
- March 19, 2024 (date) — record date for the 2024 Annual Meeting of Stockholders
- 150,000,000 (dollar_amount) — current authorized shares of common stock
- 300,000,000 (dollar_amount) — proposed increase in authorized shares of common stock
FAQ
When did CytomX Therapeutics, Inc. file this DEF 14A?
CytomX Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 4, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by CytomX Therapeutics, Inc. (CTMX).
Where can I read the original DEF 14A filing from CytomX Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by CytomX Therapeutics, Inc..
What are the key takeaways from CytomX Therapeutics, Inc.'s DEF 14A?
CytomX Therapeutics, Inc. filed this DEF 14A on April 4, 2024. Key takeaways: CytomX Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on May 15, 2024, at 1:00 p.m. Pacific Time.. The meeting will be conducted entirely online, accessible via www.virtualshareholdermeeting.com/CTMX2024.. Key agenda items include electing three directors, ratifying Ernst & Young LLP as independent auditors, and approving an amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares..
Is CytomX Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, CytomX Therapeutics, Inc. presents a relatively low-risk profile. This filing is a routine proxy statement for an annual meeting and does not contain new operational or financial information that would significantly alter the company's risk profile.
What should investors do after reading CytomX Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proposals regarding director elections, auditor ratification, and the significant increase in authorized shares before the May 15, 2024 meeting. The overall sentiment from this filing is neutral.
Risk Factors
- Increase in Authorized Shares [medium — financial]: The proposed amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares requires stockholder approval and could impact future equity offerings.
Key Dates
- 2024-05-15: 2024 Annual Meeting of Stockholders — Key date for voting on directors, auditors, and share authorization.
- 2024-03-19: Record Date — Determines which stockholders are eligible to vote at the annual meeting.
Filing Stats: 4,665 words · 19 min read · ~16 pages · Grade level 11.3 · Accepted 2024-04-04 16:31:24
Key Financial Figures
- $15,000 — n of proxies for a fee of approximately $15,000 plus associated costs and expenses. In
Filing Documents
- ny20016521x2_def14a.htm (DEF 14A) — 941KB
- logo_cytomx2.jpg (GRAPHIC) — 31KB
- ny20016521x2-pc_1.jpg (GRAPHIC) — 461KB
- ny20016521x2-pc_2.jpg (GRAPHIC) — 525KB
- ny20016521x2_pvpchart01.jpg (GRAPHIC) — 155KB
- ny20016521x2_pvpchart02.jpg (GRAPHIC) — 138KB
- 0001140361-24-017969.txt ( ) — 2744KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 15 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS ​ ​ 17 BOARD OF DIRECTORS AND CORPORATE GOVERNANCE ​ ​ 19 DIRECTOR COMPENSATION ​ ​ 28 EXECUTIVE OFFICERS ​ ​ 30
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 31
EXECUTIVE COMPENSATION TABLES
EXECUTIVE COMPENSATION TABLES ​ ​ 34 EQUITY COMPENSATION PLAN INFORMATION ​ ​ 36 PAY VERSUS PERFORMANCE ​ ​ 37 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS ​ ​ 40 OTHER MATTERS ​ ​ 41 ADDITIONAL INFORMATION ​ ​ 41 i TABLE OF CONTENTS   151 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 15, 2024 AT 1:00 P.M. PACIFIC TIME QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING PROCEDURES Why am I receiving these materials? We sent you a Notice of Internet Availability of Proxy Materials because the board of directors of CytomX Therapeutics, Inc. (the “Board”) is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders to be held on May 15, 2024 at 1:00 p.m., Pacific Time. The meeting will be held virtually, via a live webcast at www.virtualshareholdermeeting.com/CTMX2024. To attend the live webcast, you will need your unique 16-digit control number provided on the Notice of Internet Availability of Proxy Materials. We invite you to attend the annual meeting to vote on the proposals described in this Proxy Statement. However, you do not need to attend the meeting to vote your shares. Instead, you may vote by proxy over the Internet or by phone by following the instructions provided in the notice or, if you request printed copies of the proxy materials by mail, you may vote by mail. Pursuant to the rules adopted by the Securities and Exchange Commission (the “SEC”), we have elected to provide access to our Annual Meeting materials, which include this Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”), over the internet in lieu of mailing printed copies. We will begin mailing the Notice of Internet Availability to